Overview

A Study of Milvexian in Healthy Adult Females

Status:
Not yet recruiting
Trial end date:
2023-07-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the effect of milvexian given for approximately 2 weeks on (a) how the liver metabolizes other drugs (in this case one called midazolam), and (b) the pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) of an oral contraceptive pill in healthy adult females.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium
Collaborator:
Bristol Myers Squibb Company (BMS)
Treatments:
Drospirenone
Ethinyl Estradiol
Midazolam